Myeloid growth factors

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 11, Issue 10, 2013, Pages 1266-1290

  Crawford, Jeffrey ^a   Armitage, James ^b   Balducci, Lodovico ^c   Becker, Pamela Sue ^d   Blayney, Douglas W ^e   Cataland, Spero R ^f   Heaney, Mark L ^g   Hudock, Susan ^h   Kloth, Dwight D ⁱ   Kuter, David J ^j   Lyman, Gary H ^a   McMahon, Brandon ^k   Rugo, Hope S ^l   Saad, Ayman A ^m   Schwartzberg, Lee S ⁿ   Shayani, Sepideh ^o   Steensma, David P ^p   Talbott, Mahsa ^q   Vadhan Raj, Saroj ^r   Westervelt, Peter ^s   Westmoreland, Michael ^r   Dwyer, Mary ^t   Ho, Maria ^t   more..

^a DUKE CANCER INSTITUTE   (United States)

^b NEBRASKA MEDICAL CENTER   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e STANFORD CANCER INSTITUTE   (United States)

^f OHIO STATE UNIVERSITY   (United States)

^g MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^h JOHNS HOPKINS UNIVERSITY   (United States)

ⁱ FOX CHASE CANCER CENTER   (United States)

^j MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^k NORTHWESTERN UNIVERSITY   (United States)

^l UNIVERSITY OF CALIFORNIA   (United States)

^m UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

ⁿ ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^o CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^p DANA FARBER BRIGHAM AND WOMEN S CANCER CENTER   (United States)

^q VANDERBILT INGRAM CANCER CENTER   (United States)

^r UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^s BARNES JEWISH HOSPITAL   (United States)

^t NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; BILIRUBIN; BLEOMYCIN; CHOLESTEROL; CISPLATIN; CREATININE; CYCLOPHOSPHAMIDE; DACARBAZINE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; GROWTH FACTOR; IFOSFAMIDE; LIVER ENZYME; MESNA; METHOTREXATE; MYELOID GROWTH FACTOR; NITROGEN; PACLITAXEL; PREDNISONE; PROCARBAZINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; THYMOCYTE ANTIBODY; TOPOTECAN; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; UREA; VINBLASTINE; VINCRISTINE;

ABDOMINAL PAIN; ACUTE GRANULOCYTIC LEUKEMIA; ADULT RESPIRATORY DISTRESS SYNDROME; ANAPHYLAXIS; ANOREXIA; ANXIETY DISORDER; ARTHRALGIA; ASTHENIA; BLADDER CANCER; BONE PAIN; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CAPILLARY LEAK SYNDROME; CHILL; DIARRHEA; DRUG ERUPTION; DRUG FEVER; DYSPHAGIA; DYSPNEA; EDEMA; EPISTAXIS; FACE EDEMA; FEBRILE NEUTROPENIA; FLUID RETENTION; GASTROINTESTINAL HEMORRHAGE; HEART SUPRAVENTRICULAR ARRHYTHMIA; HEMATEMESIS; HEMATOPOIETIC CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOPTYSIS; HODGKIN DISEASE; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPERTENSION; HYPOMAGNESEMIA; HYPOTENSION; INSOMNIA; INTRAOCULAR HEMORRHAGE; LIVER DYSFUNCTION; LUNG HEMORRHAGE; LUNG SMALL CELL CANCER; MALAISE; METABOLIC DISORDER; MYELODYSPLASTIC SYNDROME; NAUSEA; ONCOLOGY; OVARY CANCER; PERICARDIAL EFFUSION; PERIPHERAL EDEMA; PHARYNGITIS; PLEURA EFFUSION; PRACTICE GUIDELINE; PRURITUS; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SICKLE CELL ANEMIA; SIDE EFFECT; SKIN MANIFESTATION; SOFT TISSUE SARCOMA; SPLEEN RUPTURE; TACHYCARDIA; THORAX PAIN; UREA NITROGEN BLOOD LEVEL; URINARY TRACT DISEASE; URTICARIA; VOMITING; WEIGHT REDUCTION; WHEEZING;

CHEMOTHERAPY-INDUCED FEBRILE NEUTROPENIA; CHRONIC DISEASE; COLONY-STIMULATING FACTORS; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; NEUTROPENIA; PREMEDICATION; TREATMENT OUTCOME;

EID: 84887251759     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2013.0148     Document Type: Review

References (106)

1. Lyman GH, Kuderer NM Epidemiology of febrile neutropenia. Support Cancer Ther 2003; 1: 23-35.
2. Dale DC, McCarter GC, Crawford J, Lyman GH Myelotoxicity and dose intensity of chemotherapy: reporting practices from randomized clinical trials. J Natl Compr Canc Netw 2003; 1: 440-454.
3. Dale DC. Colony-stimulating factors for the management of neutropenia in cancer patients. Drugs 2002; 62(SUPPL. 1):1-15.
4. Fortner B.V., Schwartzberg L, Tauer K., et al Impact of chemotherapy-induced neutropenia on quality of life: a prospective pilot investigation. Support Care Cancer 2005; 13: 522-528.
5. Gisselbrecht C, Haioun C, Lepage E., et al Placebo-controlled phase III study of lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) in aggressive non-Hodgkin's lymphoma: factors influencing chemotherapy administration. Groupe d'Etude des Lymphomes de l'Adulte. Leuk Lymphoma 1997; 25: 289-300.
6. Timmer-Bonte J.N., de Boo TM, Smit HJ, et al Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study. J Clin Oncol 2005; 23: 7974-7984.
7. Trillet-Lenoir V., Green J, Manegold C., et al Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 1993; 29A:319-324.
8. Vogel CL, Wojtukiewicz MZ, Carroll R.R., et al First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 2005; 23: 1178-1184.
9. Bui BN, Chevallier B, Chevreau C., et al Efficacy of lenograstim on hematologic tolerance to MAID chemotherapy in patients with advanced soft tissue sarcoma and consequences on treatment dose-intensity. J Clin Oncol 1995; 13: 2629-2636.
10. Chevallier B, Chollet P, Merrouche Y., et al Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer. J Clin Oncol 1995; 13: 1564-1571.
11. Crawford J, Ozer H, Stoller R., et al Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991; 325: 164-170.
12. Gatzemeier U, Kleisbauer J P, Drings P, et al Lenograstim as support for ACE chemotherapy of small-cell lung cancer: a phase III, multicenter, randomized study. Am J Clin Oncol 2000; 23: 393-400.
13. Muhonen T, Jantunen I, Pertovaara H., et al Prophylactic filgrastim (G-CSF) during mitomycin-C, mitoxantrone, and methotrexate (MMM) treatment for metastatic breast cancer. A randomized study. Am J Clin Oncol 1996; 19: 232-234.
14. Osby E, Hagberg H, Kvaloy S., et al CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial. Blood 2003; 101: 3840-3848.
15. Pettengell R, Gurney H, Radford J.A., et al Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial. Blood 1992; 80: 1430-1436.
16. Zinzani PL, Pavone E, Storti S., et al Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin's lymphoma. Blood 1997; 89: 3974-3979
17. Doorduijn JK, van der Holt B, van Imhoff GW, et al. CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma. J Clin Oncol 2003; 21: 3041-3050.
18. Fossa SD, Kaye SB, Mead G.M., et al Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom. J Clin Oncol 1998; 16: 716-724.
19. Citron ML, Berry DA, Cirrincione C, et al Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003; 21: 1431-1439.
20. Pfreundschuh M, Trumper L, Kloess M., et al Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 2004; 104: 634-641.
21. Bohlius J, Reiser M, Schwarzer G., Engert A. Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma. Cochrane Database Syst Rev 2004: CD003189.
22. Sung L, Nathan PC, Alibhai S.M., et al Meta-analysis: effect of prophylactic hematopoietic colony-stimulating factors on mortality and outcomes of infection. Ann Intern Med 2007; 147: 400-411.
23. Kuderer NM, Dale DC, Crawford J, Lyman GH Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 2007; 25: 3158-3167
24. Lyman GH, Dale DC, Wolff DA, et al. Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review. J Clin Oncol 2010; 28: 2914-2924.
25. Lyman GH, Kuderer NM The economics of the colony-stimulating factors in the prevention and treatment of febrile neutropenia. Crit Rev Oncol Hematol 2004; 50: 129-146.
26. Cosler LE, Eldar-Lissai A, Culakova E., et al Therapeutic use of granulocyte colony-stimulating factors for established febrile neutropenia: effect on costs from a hospital perspective. Pharmacoeconomics 2007; 25: 343-351.
27. Doorduijn JK, Buijt I, van der Holt B, et al. Economic evaluation of prophylactic granulocyte colony stimulating factor during chemotherapy in elderly patients with aggressive non-Hodgkin's lymphoma. Haematologica 2004; 89: 1109-1117.
28. Eldar-Lissai A., Cosler LE, Culakova E, Lyman GH Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy. Value Health 2008; 11: 172-179.
29. Numnum TM, Kimball KJ, Rocconi R.P., et al Pegfilgrastim for the prevention of febrile neutropenia in patients with epithelial ovarian carcinoma-a cost-effectiveness analysis. Int J Gynecol Cancer 2007; 17: 1019-1024.
30. Timmer-Bonte J.N., Adang EM, Termeer E, et al Modeling the cost effectiveness of secondary febrile neutropenia prophylaxis during standard-dose chemotherapy. J Clin Oncol 2008; 26: 290-296.
31. Food and Drug Administration. Filgrastim label information. Available at: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=97cc73cc-b5b7-458a-a933- 77b00523e193. Accessed May 1, 2013.
32. Food and Drug Administration. Pegfilgrastim label information. Available at: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fdfe5d72-6b80-435a- afa4-c5d74dd852ce. Accessed May 1, 2013.
33. Tigue CC, McKoy JM, Evens A.M., et al Granulocyte-colony stimulating factor administration to healthy individuals and persons with chronic neutropenia or cancer: an overview of safety considerations from the Research on Adverse Drug Events and Reports project. Bone Marrow Transplant 2007; 40: 185-192.
34. D'Souza A., Jaiyesimi I, Trainor L., Venuturumili P. Granulocyte colony-stimulating factor administration: adverse events. Transfus Med Rev 2008; 22: 280-290.
35. Adler BK, Salzman DE, Carabasi M.H., et al Fatal sickle cell crisis after granulocyte colony-stimulating factor administration. Blood 2001; 97: 3313-3314.
36. Grigg AP. Granulocyte colony-stimulating factor-induced sickle cell crisis and multiorgan dysfunction in a patient with compound heterozygous sickle cell/beta+ thalassemia. Blood 2001; 97: 3998-3999.
37. Kang EM, Areman EM, David-Ocampo V, et al Mobilization, collection, and processing of peripheral blood stem cells in individuals with sickle cell trait. Blood 2002; 99: 850-855.
38. Martin WG, Ristow KM, Habermann T.M., et al Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma. J Clin Oncol 2005; 23: 7614-7620.
39. Azoulay E, Attalah H, Harf A., et al Granulocyte colony-stimulating factor or neutrophil-induced pulmonary toxicity: myth or reality? Systematic review of clinical case reports and experimental data. Chest 2001; 120: 1695-1701.
40. Evens AM, Cilley J, Ortiz T., et al G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis. Br J Haematol 2007; 137: 545-552.
41. Lyman GH, Lyman CH, Agboola O. Risk models for predicting chemotherapy-induced neutropenia. Oncologist 2005; 10: 427-437.
42. Aslani A, Smith RC, Allen B.J., et al The predictive value of body protein for chemotherapy-induced toxicity. Cancer 2000; 88: 796-803.
43. Chrischilles E, Delgado DJ, Stolshek B.S., et al Impact of age and colony-stimulating factor use on hospital length of stay for febrile neutropenia in CHOP-treated non-Hodgkin's lymphoma. Cancer Control 2002; 9: 203-211
44. Lyman GH, Dale DC, Friedberg J, et al. Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study. J Clin Oncol 2004; 22: 4302-4311.
45. Lyman GH, Delgado DJ Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma. Cancer 2003; 98: 2402-2409.
46. Lyman GH, Morrison VA, Dale D.C., et al Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy. Leuk Lymphoma 2003; 44: 2069-2076.
47. Morrison VA, Picozzi V, Scott S., et al The impact of age on delivered dose intensity and hospitalizations for febrile neutropenia in patients with intermediate-grade non-Hodgkin's lymphoma receiving initial CHOP chemotherapy: a risk factor analysis. Clin Lymphoma 2001; 2: 47-56.
48. Lyman GH, Kuderer NM, Crawford J, et al Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy. Cancer 2011; 117: 1917-1927.
49. Smith TJ, Khatcheressian J, Lyman G.H., et al 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006; 24: 3187-3205.
50. Aapro MS, Bohlius J, Cameron D.A., et al 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 2011; 47: 8-32.
51. Crawford J, Dale DC, Lyman GH Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer 2004; 100: 228-237
52. Lyman GH. Risk assessment in oncology clinical practice. From risk factors to risk models. Oncology (Williston Park) 2003; 17: 8-13.
53. Hirsch BR, Lyman GH Biosimilars: are they ready for primetime in the United States? J Natl Compr Canc Netw 2011; 9: 934-942; quiz 943.
54. Zelenetz AD, Ahmed I, Braud E.L., et al NCCN Biosimilars White Paper: regulatory, scientific, and patient safety perspectives. J Natl Compr Canc Netw 2011; 9(SUPPL. 4): S1-22.
55. del Giglio A., Eniu A, Ganea-Motan D, et al XM02 is superior to placebo and equivalent to Neupogen in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy. BMC Cancer 2008; 8: 332.
56. Engert A, Griskevicius L, Zyuzgin Y., et al XM02, the first granulocyte colony-stimulating factor biosimilar, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with non-Hodgkin lymphoma receiving chemotherapy. Leuk Lymphoma 2009; 50: 374-379.
57. Gatzemeier U, Ciuleanu T, Dediu M., et al XM02, the first biosimilar G-CSF, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with small cell or non-small cell lung cancer receiving platinum-based chemotherapy. J Thorac Oncol 2009; 4: 736-740.
58. Engert A, del Giglio A, Bias P, et al Incidence of febrile neutropenia and myelotoxicity of chemotherapy: a meta-analysis of biosimilar G-CSF studies in breast cancer, lung cancer, and non-Hodgkin's lymphoma. Onkologie 2009; 32: 599-604.
59. Lubenau H, Bias P, Maly A.K., et al Pharmacokinetic and pharmacodynamic profile of new biosimilar filgrastim XM02 equivalent to marketed filgrastim Neupogen: single-blind, randomized, crossover trial. BioDrugs 2009; 23: 43-51.
60. Lubenau H, Sveikata A, Gumbrevicius G., et al Bioequivalence of two recombinant granulocyte colony-stimulating factor products after subcutaneous injection in healthy volunteers. Int J Clin Pharmacol Ther 2009; 47: 275-282.
61. American Society of Clinical Oncology. Letter to CMS regarding "Neulasta administered same day as chemotherapy". 2012. Available at: http://www.asco.org/sites/default/files/letter-to-cms-rac-audit-on-neulasta- 110912-lthd.pdf. Accessed May 1, 2013.
62. Schuman SI, Lambrou N, Robson K., et al Pegfilgrastim dosing on same day as myelosuppressive chemotherapy for ovarian or primary peritoneal cancer. J Support Oncol 2009; 7: 225-228.
63. Whitworth JM, Matthews KS, Shipman K.A., et al The safety and efficacy of day 1 versus day 2 administration of pegfilgrastim in patients receiving myelosuppressive chemotherapy for gynecologic malignancies. Gynecol Oncol 2009; 112: 601-604.
64. Burris HA, Belani CP, Kaufman P.A., et al Pegfilgrastim on the same day versus next day of chemotherapy in patients with breast cancer, non-small-cell lung cancer, ovarian cancer, and non-hodgkin's lymphoma: results of four multicenter, double-blind, randomized phase II studies. J Oncol Pract 2010; 6: 133-140.
65. Green MD, Koelbl H, Baselga J., et al A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 2003; 14: 29-35.
66. Watanabe T, Tobinai K, Shibata T., et al Phase II/III study of R-CHOP-21 versus R-CHOP-14 for untreated indolent B-cell non-Hodgkin's lymphoma: JCOG 0203 trial. J Clin Oncol 2011; 29: 3990-3998.
67. Hecht JR, Pillai M, Gollard R., et al A randomized, placebo-controlled phase II study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every-2-week chemotherapy. Clin Colorectal Cancer 2010; 9: 95-101.
68. Brusamolino E, Rusconi C, Montalbetti L., et al Dose-dense R-CHOP-14 supported by pegfilgrastim in patients with diffuse large B-cell lymphoma: a phase II study of feasibility and toxicity. Haematologica 2006; 91: 496-502.
69. Burstein HJ, Parker LM, Keshaviah A, et al Efficacy of pegflgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy. J Clin Oncol 2005; 23: 8340-8347.
70. Jones RL, Walsh G, Ashley S., et al A randomised pilot Phase II study of doxorubicin and cyclophosphamide (AC) or epirubicin and cyclophosphamide (EC) given 2 weekly with pegflgrastim (accelerated) vs 3 weekly (standard) for women with early breast cancer. Br J Cancer 2009; 100: 305-310.
71. Pirker R, Ulsperger E, Messner J., et al Achieving full-dose, on-schedule administration of ACE chemotherapy every 14 days for the treatment of patients with extensive small-cell lung cancer. Lung 2006; 184: 279-285.
72. Stull DM, Bilmes R, Kim H., Fichtl R. Comparison of sargramostim and filgrastim in the treatment of chemotherapy-induced neutropenia. Am J Health Syst Pharm 2005; 62: 83-87.
73. Thomas X, Raffoux E, Renneville A., et al Which AML subsets benefit from leukemic cell priming during chemotherapy? Long-term analysis of the ALFA-9802 GM-CSF study. Cancer 2010; 116: 1725-1732.
74. Thomas X, Raffoux E, Botton S., et al Effect of priming with granulocyte-macrophage colony-stimulating factor in younger adults with newly diagnosed acute myeloid leukemia: a trial by the Acute Leukemia French Association (ALFA) Group. Leukemia 2007; 21: 453-461.
75. Clark OA, Lyman GH, Castro A.A., et al Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol 2005; 23: 4198-4214.
76. Berghmans T, Paesmans M, Lafitte J.J., et al Therapeutic use of granulocyte and granulocyte-macrophage colony-stimulating factors in febrile neutropenic cancer patients: a systematic review of the literature with meta-analysis. Support Care Cancer 2002; 10: 181-188.
77. Garcia-Carbonero R., Mayordomo JI, Tornamira M V, et al Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial. J Natl Cancer Inst 2001; 93: 31-38.
78. Johnston E, Crawford J, Blackwell S., et al Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. J Clin Oncol 2000; 18: 2522-2528.
79. Hosing C. Hematopoietic stem cell mobilization with G-CSF. Methods Mol Biol 2012; 904: 37-47.
80. Kobbe G, Bruns I, Fenk R., et al Pegfilgrastim for PBSC mobilization and autologous haematopoietic SCT. Bone Marrow Transplant 2009; 43: 669-677
81. Kroger N, Zeller W, Fehse N, et al. Mobilizing peripheral blood stem cells with high-dose G-CSF alone is as effective as with Dexa-BEAM plus G-CSF in lymphoma patients. Br J Haematol 1998; 102: 1101-1106.
82. Barlogie B, Anaissie E, van Rhee F, et al Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br J Haematol 2007; 138: 176-185.
83. Haynes A, Hunter A, McQuaker G., et al Engraftment characteristics of peripheral blood stem cells mobilised with cyclophosphamide and the delayed addition of G-CSF. Bone Marrow Transplant 1995; 16: 359-363.
84. Matasar MJ, Czuczman MS, Rodriguez M.A., et al Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma. Blood 2013; 122: 499-506.
85. Chaudhary L, Awan F, Cumpston A., et al Peripheral blood stem cell mobilization in multiple myeloma patients treat in the novel therapy-era with plerixafor and G-CSF has superior efficacy but significantly higher costs compared to mobilization with low-dose cyclophosphamide and G-CSF. J Clin Apher 2013, in press.
86. Dugan MJ, Maziarz RT, Bensinger W.I., et al Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization. Bone Marrow Transplant 2010; 45: 39-47.
87. Gopal AK, Karami M, Mayor J., et al The effective use of plerixafor as a real-time rescue strategy for patients poorly mobilizing autologous CD34(+) cells. J Clin Apher 2012; 27: 81-87.
88. Milone G, Tripepi G, Martino M., et al Early measurement of CD34+ cells in peripheral blood after cyclophosphamide and granulocyte colony-stimulating factor treatment predicts later CD34+ mobilisation failure and is a possible criterion for guiding "on demand" use of plerixafor. Blood Transfus 2013; 11: 94-101.
89. Costa LJ, Kramer C, Hogan K.R., et al Pegfilgrastimversus filgrastim-based autologous hematopoietic stem cell mobilization in the setting of preemptive use of plerixafor: efficacy and cost analysis. Transfusion 2012; 52: 2375-2381.
90. Bensinger WI, Weaver CH, Appelbaum F.R., et al Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor. Blood 1995; 85: 1655-1658.
91. Cavallaro AM, Lilleby K, Majolino I., et al Three to six year follow-up of normal donors who received recombinant human granulocyte colony-stimulating factor. Bone Marrow Transplant 2000; 25: 85-89.
92. Rinaldi C, Savignano C, Pasca S., et al Efficacy and safety of peripheral blood stem cell mobilization and collection: a single-center experience in 190 allogeneic donors. Transfusion 2012; 52: 2387-2394.
93. Lane TA, Ho AD, Bashey A, et al Mobilization of blood-derived stem and progenitor cells in normal subjects by granulocyte-macrophage- and granulocyte-colony-stimulating factors. Transfusion 1999; 39: 39-47.
94. Lonial S, Akhtari M, Kaufman J., et al Mobilization of hematopoietic progenitors from normal donors using the combination of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor results in fewer plasmacytoid dendritic cells in the graft and enhanced donor T cell engraftment with Th1 polarization: results from a randomized clinical trial. Biol Blood Marrow Transplant 2013; 19: 460-467.
95. Sohn SK, Kim JG, Seo K.W., et al GM-CSF-based mobilization effect in normal healthy donors for allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant 2002; 30: 81-86.
96. Linch DC, Milligan DW, Winfield D.A., et al G-CSF after peripheral blood stem cell transplantation in lymphoma patients significantly accelerated neutrophil recovery and shortened time in hospital: results of a randomized BNLI trial. Br J Haematol 1997; 99: 933-938.
97. Klumpp TR, Mangan KF, Goldberg S.L., et al Granulocyte colony-stimulating factor accelerates neutrophil engraftment following peripheral-blood stem-cell transplantation: a prospective, randomized trial. J Clin Oncol 1995; 13: 1323-1327.
98. Lee SM, Radford JA, Dobson L, et al Recombinant human granulocyte colony-stimulating factor (filgrastim) following high-dose chemotherapy and peripheral blood progenitor cell rescue in high-grade non-Hodgkin's lymphoma: clinical benefits at no extra cost. Br J Cancer 1998; 77: 1294-1299.
99. Spitzer G, Adkins DR, Spencer V, et al Randomized study of growth factors post-peripheral-blood stem-cell transplant: neutrophil recovery is improved with modest clinical benefit. J Clin Oncol 1994; 12: 661-670.
100. Kawano Y, Takaue Y, Mimaya J., et al Marginal benefit/disadvantage of granulocyte colony-stimulating factor therapy after autologous blood stem cell transplantation in children: results of a prospective randomized trial. The Japanese Cooperative Study Group of PBSCT. Blood 1998; 92: 4040-4046.
101. Castagna L, Bramanti S, Levis A., et al Pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous peripheral blood stem cell support. Ann Oncol 2010; 21: 1482-1485.
102. Ziakas PD, Kourbeti IS Pegfilgrastim vs. filgrastim for supportive care after autologous stem cell transplantation: can we decide? Clin Transplant 2012; 26: 16-22.
103. Battiwalla M, McCarthy PL Filgrastim support in allogeneic HSCT for myeloid malignancies: a review of the role of G-CSF and the implications for current practice. Bone Marrow Transplant 2009; 43: 351-356.
104. Nemunaitis J, Rabinowe SN, Singer J.W., et al Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. N Engl J Med 1991; 324: 1773-1778.
105. Ippoliti C, Przepiorka D, Giralt S., et al Low-dose non-glycosylated rhGM-CSF is effective for the treatment of delayed hematopoietic recovery after autologous marrow or peripheral blood stem cell transplantation. Bone Marrow Transplant 1993; 11: 55-59.
106. Dale DC, Bonilla MA, Davis M.W., et al A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (filgrastim) for treatment of severe chronic neutropenia. Blood 1993; 81: 2496-2502.